[1]
|
Nagarajan, S. and Whitaker, P. (2018) Management of Adverse Reactions to First-Line Tuberculosis Antibiotics. Current Opinion in Allergy and Clinical Immunology, 18, 333-341. https://doi.org/10.1097/ACI.0000000000000462
|
[2]
|
Saukkonen, J.J., Cohn, D.L., Jasmer, R.M., Schenker, S., Jereb, J.A., Nolan, C.M., Peloquin, C.A., Gordin, F.M., Nunes, D., Strader, D.B., Bernardo, J., Venkataramanan, R. and Sterling, T.R. (2006) An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. American Journal of Respiratory and Critical Care Medicine, 174, 935-952. https://doi.org/10.1164/rccm.200510-1666ST
|
[3]
|
Tostmann, A., Boeree, M.J., Aarnoutse, R.E., de Lange, W.C., van der Ven, A.J. and Dekhuijzen, R. (2008) Antituberculosis Drug-Induced Hepatotoxicity: Concise Up-to-Date Review. Journal of Gastroenterology and Hepatology, 23, 192-202.
https://doi.org/10.1111/j.1440-1746.2007.05207.x
|
[4]
|
Shang, P., Xia, Y., Liu, F., Wang, X., Yuan, Y., Hu, D., Tu, D., Chen, Y., Deng, P., Cheng, S., Zhou, L., Ma, Y., Zhu, L., Gao, W., Wang, H., Chen, D., Yang, L., He, P., Wu, S., Tang, S., Lv, X., Shu, Z., Zhang, Y., Yang, Z., Chen, Y., Li, N., Sun, F., Li, X., He, Y., Garner, P. and Zhan, S. (2011) Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China. PLoS ONE, 6, e21836.
https://doi.org/10.1371/journal.pone.0021836
|
[5]
|
Song, J.H., Yoon, S.Y., Park, T.Y., Heo, E.Y., Kim, D.K., Chung, H.S. and Lee, J.K. (2019) The Clinical Impact of Drug-Induced Hepatotoxicity on Anti-Tuberculosis Therapy: A Case Control Study. Respiratory Research, 20, 283.
https://doi.org/10.1186/s12931-019-1256-y
|
[6]
|
Ramappa, V. and Aithal, G.P. (2013) Hepatotoxicity Related to Anti-Tuberculosis Drugs: Mechanisms and Management. Journal of Clinical and Experimental Hepatology, 3, 37-49. https://doi.org/10.1016/j.jceh.2012.12.001
|
[7]
|
(2019) EASL Clinical Practice Guidelines: Drug-Induced Liver Injury. Journal of Hepatology, 70, 1222-1261. https://doi.org/10.1016/j.jhep.2019.02.014
|
[8]
|
Marjani, M., Fahim, F., Sadr, M., Kazempour Dizaji, M., Moniri, A., Khabiri, S., Tabarsi, P. and Velayati, A.A. (2019) Evaluation of Silymarin for Management of Anti-Tuberculosis Drug Induced Liver Injury: A Randomized Clinical Trial. Gastroenterology and Hepatology from Bed to Bench, 12, 138-142.
|
[9]
|
Tao, L., Qu, X., Zhang, Y., Song, Y. and Zhang, S.X. (2019) Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials. Can Journal of Gastroenterology and Hepatology, 2019, Article ID: 3192351. https://doi.org/10.1155/2019/3192351
|
[10]
|
Xu, L., Zhang, F., Xu, C., Liu, K.G., Wu, W. and Tian, Y.X. (2017) Is the Prophylactic Use of Hepatoprotectants Necessary in Anti-Tuberculosis Treatment? Chemotherapy, 62, 269-278. https://doi.org/10.1159/000465515
|
[11]
|
Chascsa, D.M.H. and Lindor, K.D. (2020) Emerging Therapies for PBC. Journal of Gastroenterology, 55, 261-272. https://doi.org/10.1007/s00535-020-01664-0
|
[12]
|
Simental-Mendia, M., Sanchez-Garcia, A. and Simental-Mendia, L.E. (2020) Effect of Ursodeoxycholic Acid on Liver Markers: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Trials. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.14311
|
[13]
|
Hassan, A. and Fontana, R.J. (2019) The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Liver International, 39, 31-41.
https://doi.org/10.1111/liv.13931
|
[14]
|
Arai, T., Kogi, K., Honda, Y., Suzuki, T., Kawai, K., Okamoto, M., Fujioka, T. and Murata, N. (2018) Lorazepam as a Cause of Drug-Induced Liver Injury. Case Reports in Gastroenterology, 12, 546-550. https://doi.org/10.1159/000492209
|
[15]
|
Asgarshirazi, M., Shariat, M., Dalili, H. and Keihanidoost, Z. (2015) Ursodeoxycholic Acid Can Improve Liver Transaminase Quantities in Children with Anticonvulsant Drugs Hepatotoxicity: A Pilot Study. Acta Medica Iranica, 53, 351-355.
http://acta.tums.ac.ir/index.php/acta/article/view/4878
|
[16]
|
Bordbar, M., Shakibazad, N., Fattahi, M., Haghpanah, S. and Honar, N. (2018) Effect of Ursodeoxycholic Acid and Vitamin E in the Prevention of Liver Injury from Methotrexate in Pediatric Leukemia. Turk Journal of Gastroenterology, 29, 203-209.
https://doi.org/10.5152/tjg.2018.17521
|
[17]
|
Fernandes, C.T., Iqbal, U., Tighe, S.P. and Ahmed, A. (2019) Kratom-Induced Cholestatic Liver Injury and Its Conservative Management. Journal of Investigative Medicine High Impact Case Reports, 7, 1-4.
https://doi.org/10.1177/2324709619836138
|
[18]
|
Ito, T., Ozaki, Y., Son, Y., Nishizawa, T., Amuro, H., Tanaka, A., Tamaki, T. and Nomura, S. (2014) Combined Use of Ursodeoxycholic Acid and Bosentan Prevents Liver Toxicity Caused by Endothelin Receptor Antagonist Bosentan Monotherapy: Two Case Reports. Journal of Medical Case Reports, 8, 250.
https://doi.org/10.1186/1752-1947-8-250
|
[19]
|
Kurokawa, K., Hara, M., Iwakami, S.I., Genda, T., Iwakami, N., Miyashita, Y., Fujioka, M., Sasaki, S. and Takahashi, K. (2019) Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma. Internal Medicine, 58, 3283-3287. https://doi.org/10.2169/internalmedicine.2591-18
|
[20]
|
Sawada, K., Shonaka, T., Nishikawa, Y., Hasegawa, K., Hayashi, H., Hasebe, T., Nakajima, S., Ikuta, K., Fujiya, M., Furukawa, H. and Okumura, T. (2019) Successful Treatment of Nivolumab-Related Cholangitis with Prednisolone: A Case Report and Review of the Literature. Internal Medicine, 58, 1747-1752.
https://doi.org/10.2169/internalmedicine.2330-18
|
[21]
|
Wree, A., Dechene, A., Herzer, K., Hilgard, P., Syn, W.K., Gerken, G. and Canbay, A. (2011) Steroid and Ursodesoxycholic Acid Combination Therapy in Severe Drug-Induced Liver Injury. Digestion, 84, 54-59. https://doi.org/10.1159/000322298
|
[22]
|
Wang, D.Q. and Carey, M.C. (2014) Therapeutic Uses of Animal Biles in Traditional Chinese Medicine: An Ethnopharmacological, Biophysical Chemical and Medicinal Review. World Journal of Gastroenterology, 20, 9952-9975.
https://doi.org/10.3748/wjg.v20.i29.9952
|
[23]
|
Alpana, M., Daga, M.K., Aggarwal, S. and Nidhi, A. (2015) Treatment for Tuberculosis in a Patient with Dubin-Johnson Syndrome. BMJ Case Reports, 2015, pii: bcr2015211123. https://doi.org/10.1136/bcr-2015-211123
|
[24]
|
Kataoka, K., Kono, Y., Sugimoto, M., Furuichi, Y., Shichiri, M. and Tanaka, Y. (2010) Hepatocyte-Protective and Anti-Oxidant Effects of Rifampicin on Human Chronic Hepatitis C and Murine Acute Hepatocyte Disorder. Experimental and Therapeutic Medicine, 1, 1041-1047. https://doi.org/10.3892/etm.2010.159
|
[25]
|
Saito, Z., Kaneko, Y., Kinoshita, A., Kurita, Y., Odashima, K., Horikiri, T., Yoshii, Y., Seki, A., Seki, Y., Takeda, H. and Kuwano, K. (2016) Effectiveness of Hepatoprotective Drugs for Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Retrospective Analysis. BMC Infectious Diseases, 16, Article No. 668.
https://doi.org/10.1186/s12879-016-2000-6
|
[26]
|
Lang, S., Ortmann, J., Rostig, S. and Schiffl, H. (2019) Ursodeoxycholic Acid Attenuates Hepatotoxicity of Multidrug Treatment of Mycobacterial Infections: A Prospective Pilot Study. International Journal of Mycobacteriology, 8, 89-92.
https://doi.org/10.4103/ijmy.ijmy_159_18
|
[27]
|
Borzakova, S.N. and Reyzis, A.R. (2018) Principles of Diagnosis and Therapy of Drug-Induced Liver Injury in Children with Tuberculosis. Rossiyskiy Vestnik Perinatologii i Pediatrii, 63, 91-97. https://doi.org/10.21508/1027-4065-2018-63-3-91-97
|
[28]
|
Chen, X., Xu, J., Zhang, C., Yu, T., Wang, H., Zhao, M., Duan, Z.H., Zhang, Y., Xu, J.M. and Xu, D.X. (2011) The Protective Effects of Ursodeoxycholic Acid on Isoniazid plus Rifampicin Induced Liver Injury in Mice. European Journal of Pharmacology, 659, 53-60. https://doi.org/10.1016/j.ejphar.2011.03.007
|